Loading chat...
US HB7352
Bill
Status
2/4/2026
Primary Sponsor
Earl Carter
Click for details
AI Summary
-
Establishes a subscription-based contract program allowing the HHS Secretary to pay drug sponsors $75 million to $300 million annually for up to 10 years for innovative antimicrobial drugs that treat "urgent" or "serious" CDC-listed pathogens and address unmet medical needs
-
Appropriates $6 billion in emergency funding for fiscal year 2026 to implement the program, with up to 6.5% available for antimicrobial stewardship and surveillance activities
-
Creates a 15-member Critical Need Antimicrobial Advisory Group to help develop scoring criteria for eligible drugs based on patient care contributions, innovative characteristics, and public health benefits
-
Requires contract recipients to ensure commercial drug availability, track and report resistance data, implement appropriate use education programs, maintain reliable supply chains, and meet environmental manufacturing standards
-
Establishes grant programs through CDC to support antimicrobial stewardship in hospitals, skilled nursing facilities, and outpatient settings, with priority given to rural hospitals, critical access hospitals, and safety-net facilities
Legislative Description
PASTEUR Act of 2026 Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2026
Health
Last Action
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2/4/2026